hepatic impairment study for lorlatinib in cancer patients

Conditions: Advanced Cancers

Summary: this is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

this will be a phase 1, open label, multi center, multiple dose, non randomized, phase 1 clinical trial of lorlatinib in advanced cancer patients with varying degrees of hepatic impairment and necessary age , weight , and gender matched prospect normal hepatic function patients. this study is intended to evaluate the potential effect of hepatic impairments on the pk and safety of lorlatinib after daily administration of lorlatinib and to provide dosing recommendation for patients with varied degree of hepatic impairment if possible. patients in the study will be assigned to different groups (a1, normal liver function, control for group b; a2, normal liver function, control for group c; b, mild hepatic impairment; c, moderate hepatic impairment; d, severe hepatic impairment) according to their liver function. the enrollment of approximately 76 advanced cancer patients is anticipated in this study in order to have 8 pk-evaluable patients in each of groups a1, a2, b and c, and 6 pk-evaluable patients in group d for final statistical analysis. evaluable patients are those who complete the planned pk sample collection on cycle 2 day 1 and have no lorlatinib dose modification until completion of cycle 2 day 1 pk evaluation. patients who are not evaluable for pk will be replaced. each patient will be treated with repeated oral once daily doses of lorlatinib in 21-day cycles until disease progression, patient refusal, or unacceptable toxicity occurs. the dose schedule may be modified as necessary for individual patients according to tolerability.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective; * biliary obstruction with a biliary drain or stent; * neurologically stable gliomas and brain metastases; * ecog performance status of 0, 1, or 2; * adequate bone marrow function; * adequate pancreatic function; * adequate renal function; * female patients with negative pregnancy test exclusion criteria: * untreated esophageal varices; uncontrolled ascites; * episodes of hepatic encephalopathy within the last 4 weeks; * spinal cord compression; major surgery within 4 weeks prior to enrollment; * radiation therapy within 2 weeks prior to enrollment; * last anti-cancer treatment within 2 weeks prior to screening; * previous high-dose chemotherapy requiring stem cell rescue; * prior to irradiation to \>25% of the bone marrow; * gastrointestinal abnormalities; * known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet; * clinically significant bacterial, fungal or viral infections for non-liver cancer patients; * clinically significant cardiovascular disease; * uncontrolled hypertension; acute pancreatitis with predisposing characteristics; * history of grade 3 or 4 interstitial fibrosis or interstitial lung disease; * active hemoelysis or evidence of biliary sepsis; * prior major gastrointestinal surgery; * concurrent use of known strong cyp3a inhibitors, inducers and p-gp substrates with a narrow therapeutic index; * concurrent use of cyp3a substrates with narrow therapeutic indices; * prior treatment with lorlatinib; active bleeding disorder

Keywords: hepatic impairment lorlatinib cancer pharmacokinetic lung cancer